Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Duramed (DRMD) Synthetic Estrogen Product -- Ignore unavailable to you. Want to Upgrade?

To: Doug Bean who wrote (1361)	7/28/1999 8:19:00 AM
From: vestor	Read Replies (1) \| Respond to of 1837

We are approaching bargain prices again. The BC pill and the Progesterin Cenestin combo drug, upon approval, should add significant revenue to DRMD's already significantly improved financial picture. The drug sector as evidenced by Merck, Smith Kline, etc. is currently taking a back seat to this high tech rebound. However the baby boom population, a significant, number of people is approaching the age area where more and more presciption drugs enter their lives. If one followed the demographics and was ahead of the curve you did well. The key is to be ahead of the curve and buy the stocks while they are still cheap. DRMD is positioning itself to be the drug provider of choice for womens health at least in certain areas. Although this process is slow we should see qtr. over qtr. dramatic improvement to DRMD's bottom line. Think about the odds of DRMD not getting the Cenestin/Progesterine combo. This approval, to me, is as certain as I was that Cenestin would be approved. Once the bone marrow studies are complete this is a slam dunk for a large upward move to the mid 20's. I would treat this sector based weakness as a time to quietly accumulate shares for the better days ahead.